The human trials
Amycretin's peer-reviewed human record is four Lancet papers. Two are the small early-phase trials published in 2025: a…
What the human data actually shows
Amycretin's peer-reviewed human record is four Lancet papers. Two are the small early-phase trials published in 2025: an oral phase 1 (Gasiorek) and a subcutaneous phase 1b/2a (Dahl), backed by a rodent pharmacology paper. The other two appeared on 30 July 2026 and are the oral and subcutaneous halves of a phase 2 type 2 diabetes dose-finding trial, first presented at ADA in June 2026. No phase 3 has reported. This unit walks through exactly what each showed and, just as importantly, what it did not.
The durable skill here is reading an early result honestly: separating a striking small-arm signal from an established efficacy result, and citing the peer-reviewed paper rather than a press-release topline.
Key terms
The evidence so far
Amycretin's evidence base is young and shallow. From the hormone biology worked out over decades, the drug reached its first human trials, and by mid-2025 two early-phase papers plus a preclinical paper appeared together, prompting the move to phase 3. The confirmatory trials began enrolling in 2026, and the phase 2 diabetes results were published that July.
Notice how compressed this is: amycretin went from first human data to a phase 3 program in about a year, on the strength of early signals. That is a normal, promising trajectory, but it means the confirmatory evidence, the kind that supports approval, has not been generated yet. Everything below is dose-finding.
The 2026 papers are the first amycretin results in people with type 2 diabetes, and the first from a multi-country trial rather than a single center. They ran for 36 weeks across 83 sites in 11 countries. Their main measure was HbA1c, the blood test that averages blood sugar over about three months. In the 186-participant oral trial, HbA1c fell about 1.4 percentage points on the highest dose (50 mg daily). In the 262-participant injection trial it fell about 1.7 points on the highest dose (40 mg weekly). Subtracting what placebo did leaves about 1.1 and 1.6 points.
AdvancedWhy publishing phase 1 in a top journal is unusual
Most phase 1 trials never reach a journal like The Lancet; they are small safety studies. Amycretin's early trials were published there because the weight-loss signals were striking and the molecule is genuinely novel. That visibility is a double-edged sword: it earns deserved attention but also lets small-arm numbers circulate as if they were phase 3 results. The prestige of the venue does not upgrade the maturity of the evidence.